TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged 18 to 80 years. Females participating in the study must be either of non-childbearing potential, or willing to use a highly effective contraceptive method.~* Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to primary osteoarthritis.~* Patients experiencing pain at rest of at least moderate intensity the day after surgery.~Exclusion Criteria:~* Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are contraindicated.~* Patients with clinically significant abnormalities in vital signs, safety laboratory tests and 12-lead ECG at screening.~* Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.~* Patients using and not suitable to withdraw analgesics other than those specified in the protocol.~* Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.~* Pregnant and breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DKP/TRAM followed by DKP/TRAM (Type: EXPERIMENTAL): Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
- DKP followed by DKP (Type: ACTIVE_COMPARATOR): Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
- TRAM followed by TRAM (Type: ACTIVE_COMPARATOR): Tramadol-single dose followed by Tramadol-multiple doses
- Placebo followed by DKP/TRAM (Type: OTHER): Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
- Placebo followed by DKP (Type: OTHER): Placebo single dose followed by Dexketoprofen-multiple doses
- Placebo followed by TRAM (Type: OTHER): Placebo single dose followed by Tramadol-multiple doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is a male between 40 and 95 years of age~* Has osteoporosis~* Has anatomy suitable for dual energy x-ray absorptiometry (DXA) scan of the lumbar spine and and hip~* Is ambulatory~Exclusion Criteria:~* Is currently on oral bisphosphonates or other treatment for osteoporosis~* Had previous hip fragility fracture and is a candidate for standard of care therapy~* Has had a fragility fracture (vertebral or non-vertebral fractures indicating reduced bone strength) within 12 months~* Has had more then one previous vertebral fracture~* Has been diagnosed with metabolic bone disorder other than osteoporosis~* Is Vitamin D deficient~* Has a history of renal stones~* Has active parathyroid disease~* Has history of thyroid disease not well controlled by medication~* Is diagnosed with secondary osteoporosis~* Has a daily calcium intake of \<1,200 mg and is unwilling to take study prescribed supplements or increase dietary intake, such that his daily calcium intake is at least 1200 mg~* Has a history of malignancy ≤5 years prior to signing informed consent~* Has been diagnosed with hypogonadism due to causes that affect multiple organ and body systems

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg once weekly (Type: EXPERIMENTAL): Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
- Placebo once weekly (Type: PLACEBO_COMPARATOR): Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers over age 21~Exclusion Criteria:~* pregnancy~* alcoholism~* diabetes~* kidney/bladder stones~* kidney disease~* liver disease~* stomach ulcer~* organ transplant patients~* dialysis patients~* subjects with alcohol allergies~* subjects taking the following medications: activated charcoal, ampicillin, carbamazepine, cephaloridine, cloxacillin, methicillin, nitroglycerine, oxacillin, penicillin G, or quinicillin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- all study participants (Type: EXPERIMENTAL): subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women with persistent plantar hyperhidrosis with limitation to their usual activities.~Exclusion Criteria:~* pregnancy,~* breastfeeding,~* glaucoma,~* use of tricyclic medications,~* prior use of anticholinergic~* side effects exacerbated, such as diarrhea, gastritis, constipation or dry mouth.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Oxybuynin, hyperhidrosis (Type: ACTIVE_COMPARATOR): None
- placebo - sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* having clinical AD diagnosis according to the NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association) criteria~* being 60 years and older~* having Clinical Dementia Rating Scale (CDR) scores 1 or 2~* living independently~Exclusion Criteria:~* not being able to walk independently,~* having physical disabilities,~* having a history of alcohol / substance abuse,~* having head trauma~* having epileptic seizures

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMS group (Type: EXPERIMENTAL): In the TMS group (n=10) rTMS was applied to the bilateral dorsolateral prefrontal cortex (DLPFC) at 20 Hz, for 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
- AE group (Type: EXPERIMENTAL): AE group (n=9) received a moderate- intensity aerobic exercise program lasting 50 minutes per session, 5 consecutive days per week for over 2 weeks (totally 10 sessions) in addition to the pharmacological treatment.
- Control group (Type: ACTIVE_COMPARATOR): No additional intervention was given to the patients in the control group (n=8) and participants were only treated pharmacologically.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Term Refractive and Ocular Parameter Changes After Topical Atropine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who had an SER of -0.5 diopters or less in their eyes.~Exclusion Criteria:~* Patients who had already been undergoing cycloplegic treatment for myopia before.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 0.125% atropine group (Type: EXPERIMENTAL): patients used the 0.125 % atropine eyedrop every night before sleep for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient does not have hypertension or has Stage I or II hypertension and is taking \< 3 anti-hypertension medications~* Patient is willing to discontinue all anti-hypertensive medications during study~* Patient is willing to refrain from drinking alcohol for 24 hours prior to each study visit and is willing to limit intake at other times during the study to 2 drinks per day~* Patient agrees to avoid caffeine for 24 hours prior to each study visit. At other times during study, daily caffeine intake should not exceed 4 cups of coffee (or equivalent)~* Patient will avoid strenuous physical activity during study~* Patient is a nonsmoker or has not smoked for the last 3 months~Exclusion Criteria:~* Patient has metal implants in the leg or artificial limbs~* Patient has had a lower limb amputation, malformation, alterations in leg muscles, or a history of musculoskeletal disease~* Patient has used oral contraceptive pills or hormone replacement therapy within 3 months of screening~* Patient has a history of stroke or seizures~* Patient has a history of cancer, except that which was treated at least 10 years prior to screening and shows no evidence of recurrence

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): amlodipine
- 2 (Type: PLACEBO_COMPARATOR): Placebo to amlodipine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Weighs greater than or equal to (\>=) 45 kilogram (kg) and has a body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.~Exclusion Criteria:~1. Has received TAK-831 in a previous clinical study.~2. Has poor peripheral venous access.~3. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of study drug.~4. Has any dietary restrictions or preferences that may interfere with the conduct of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- TAK-831 400 mg Fasted + TAK-831 400 mg Fed (Type: EXPERIMENTAL): TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
- TAK-831 400 mg Fed + TAK-831 400 mg Fasted (Type: EXPERIMENTAL): TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's parent has provided informed consent and subject has provided assent~* Children Age 2 to less than 18 years~* Diagnosed with chronic kidney disease~* Diagnosed with secondary hyperparathyroidism receiving hemodialysis,~* Weighing at least 7 kg~* Laboratory results within specified range.~Exclusion Criteria:~* Currently receiving treatment in another investigation device or drug study~* Subject has received cinacalcet therapy within 30 days~* History of prolongation QT interval~* Subject is taking any medications that are on the QT prolongation medication list~* Electrocardiograph (ECG) measurements within specified range.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Etelcalcetide (Type: EXPERIMENTAL): Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Endometrial Compaction Caused by Progesterone Effect on Pregnancy Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Woman aged 18-40 years~2. Presence of high quality (\>2BB) blastocyst~3. Hormonal(estrogen and progesterone) frozen- thawed embryo transfer cycles~4. presence of high quality blastocyst cryopreserved by vitrification method.~5. A single embryo transfer~Exclusion Criteria:~1. Presence of uterine pathology~2. Participants whose optimal endometrial image cannot be obtained due to uterine position~3. Participants whose treatments were canceled for any reason before embryo transfer~4. Participants which had embryo transfer on the day 2 or 3 (at the cleavage stage)~5. Participants who had 2 embryo transfer~6. Presence of low quality (\<2BB) blastocyst~7. \> 15% loss of viability in the embryo during embryo thawing

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- with endometrial compaction (Type: None): Participants who have endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement
- without endometrial compaction (Type: None): Participants who have not endometrial compaction caused by progesterone effects on undergoing frozen embryo transfer with artificial hormone replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 30 and 80 inclusive.~* Has not worn contact lenses for at least 1 month prior to the study and agrees to not wear contact lenses during study.~* Oral medications stable 1 month prior to study.~* Oral medications anticipated to be stable during 60 day study.~* Patient is in generally good \& stable overall health.~* Patient likely to comply with eye drop regimen, study guidelines \& study visits.~* Corneal stain \> 1+ or Conjunctival stain \> 1+ or OSDI equal or \> 5 or using regular artificial tears at least on average twice daily.~* Informed consent signed.~Exclusion Criteria:~* History of Stevens-Johnson Syndrome or Ocular Pemphigoid.~* Punctal plugs inserted or punctal cautery in the past 3 months.~* Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.~* History of liver disease.~* Pregnant or lactating women.~* Severe clinical vitamin deficiencies or history of vitamin overdose.~* Highly variable vitamin intake.~* Unstable use of systemic or topical medications known to create dry eye.~* Corneal pathology, which could, of itself, cause an ocular surface disorder.~* Use of glaucoma medications, topical or oral.~* Unstable diabetes mellitus.~* Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.~* Use of topical steroids or Restasis within the past 1 month.~* Use of other topical ocular agents other than tear replacements within the past 1 week.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Helicobacter pylori infected patients \> 18 years~Exclusion Criteria:~* previous H. pylori eradication treatment;~* Use of proton pump inhibitors, H2-receptor antagonists, bismuth preparations and antibiotics in the previous 4 weeks;~* Concomitant anticoagulant or ketoconazole use, due to the potential of interaction with the study medications;~* Zollinger-Ellison syndrome;~* Previous surgery of the esophagus and/or upper gastrointestinal tract (with the exception of appendectomy, polypectomy and cholecystectomy);~* Severe or unstable cardiovascular, pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematological disorder; any other clinically significant medical condition that could increase the risk to the study participants; malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer or Barrett esophagus with high grade dysplasia;~* Drug or medication abuse within the past year;~* Severe psychiatric or neurological disorders;~* Pregnant or nursing women sexually active women of child bearing potential who were not willing to practice medically acceptable contraception (oral contraceptives; inject able/implantable or mechanical devices as well as vasectomy of the sexual partner) for the entire duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab for Prevention of Chronic GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation~* Peripheral blood stem cells must have been used as the stem cell source~* Patients must have received transplantation from donors who are identical at 6 HLA loci, or mismatched at no more than 1 locus.~* Patients who have undergone a non-myeloablative stem cell transplant must have \> 80% donor hematopoiesis within 30 days of study enrollment~* 18 years of age or older~* Performance Status 0-2~* Life expectancy of \> 100 days~* Subjects with CLL are eligible, if there is no more than 20% residual leukemia in the bone marrow at the time of study entry~Exclusion Criteria:~* Evidence of relapsed or residual malignancy within 30 days of trial entry~* Highly aggressive B cell malignancy, such as Burkitt's lymphoma or Burkitt's-like lymphoma~* Allogeneic stem cell transplantation using a single or multiple umbilical cord blood units or using bone marrow~* Evidence of any active uncontrolled infection, or evidence of natural exposure to Hepatitis B, Hepatitis C or HIV~* Evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater than ongoing Stage I cutaneous acute GVHD~* GVHD with chronic features diagnosed prior to day +100 or prior to enrollment~* Participation in a clinical trial evaluating another preventative strategy for chronic GVHD, or ongoing participation in a clinical trial for therapy of acute GVHD~* No Donor Lymphocyte Infusion (DLI) prior to day 100 and not plans for a DLI in the upcoming 30 days~* Heart failure uncontrolled by medications~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete